HC Wainwright Issues Pessimistic Outlook for EPRX Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Research analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for Eupraxia Pharmaceuticals in a research report issued on Thursday, May 14th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.25) per share for the quarter, down from their previous forecast of ($0.20). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at ($0.79) EPS.

Several other brokerages have also recently weighed in on EPRX. Wall Street Zen cut Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. William Blair began coverage on Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Trading Down 3.3%

Shares of EPRX opened at $6.69 on Tuesday. The business’s 50-day moving average price is $7.26 and its 200-day moving average price is $7.31. Eupraxia Pharmaceuticals has a twelve month low of $3.67 and a twelve month high of $9.32. The stock has a market cap of $404.28 million, a PE ratio of -6.37 and a beta of 1.19. The company has a quick ratio of 19.31, a current ratio of 19.31 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EPRX. Royal Bank of Canada increased its position in shares of Eupraxia Pharmaceuticals by 21.1% in the first quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after purchasing an additional 59,683 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after purchasing an additional 16,017 shares during the last quarter. Bank of America Corp DE increased its position in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares during the last quarter. Ingalls & Snyder LLC increased its position in shares of Eupraxia Pharmaceuticals by 58.9% in the third quarter. Ingalls & Snyder LLC now owns 59,100 shares of the company’s stock worth $349,000 after purchasing an additional 21,900 shares during the last quarter. Finally, Guardian Partners Inc. bought a new position in shares of Eupraxia Pharmaceuticals in the third quarter worth approximately $147,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.